PRECIGEN, INC. Current Assets
PRECIGEN, INC. (PGEN) had Current Assets of $134.38 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-04
- 2026-06-30: Assets, Current $134.38M.
- 2026-03-31: Assets, Current $101.67M.
- 2025-12-31: Assets, Current $115.23M.
- 2025-09-30: Assets, Current $129.60M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $134.38M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $101.67M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $115.23M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $129.60M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $62.76M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $84.60M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $102.41M 10-K · filed 2026-03-25 |
| 2024-09-30 | $34.51M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $23.71M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $49.55M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $68.75M 10-K · filed 2025-03-19 |
| 2023-09-30 | $92.99M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $105.63M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $137.74M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $118.16M 10-K · filed 2024-03-19 |
| 2022-09-30 | $162.81M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $164.62M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $154.94M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $156.63M 10-K · filed 2023-03-06 |
| 2021-09-30 | $153.09M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $156.69M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $144.12M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $148.95M 10-K · filed 2022-03-01 |
| 2020-09-30 | $151.12M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $173.00M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $189.38M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $234.64M 10-K · filed 2021-03-01 |
| 2019-09-30 | $157.33M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $183.16M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $232.18M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $285.48M 10-K · filed 2020-03-02 |
| 2018-09-30 | $310.47M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $147.81M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $187.54M 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $154.05M 10-K · filed 2019-03-01 |
| 2017-09-30 | $179.74M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $234.12M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $281.67M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $315.18M 10-K · filed 2018-03-01 |
| 2016-09-30 | $316.22M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $345.66M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $336.54M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $323.80M 10-K · filed 2017-03-01 |
| 2015-09-30 | $302.43M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $359.54M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $238.80M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $174.77M 10-K · filed 2016-02-29 |
| 2014-09-30 | $181.30M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $188.30M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $232.93M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $187.56M 10-K · filed 2015-03-02 |
| 2013-09-30 | $206.24M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $134.32M 10-Q/A · filed 2013-10-21 |
| 2012-12-31 | $13.53M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |